Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Expected to Post Quarterly Sales of $75.82 Million

Equities analysts expect that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will report sales of $75.82 million for the current quarter, according to Zacks. Four analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The highest sales estimate is $78.40 million and the lowest is $71.20 million. Amphastar Pharmaceuticals reported sales of $71.04 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.7%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 14th.

According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full year sales of $323.90 million for the current fiscal year, with estimates ranging from $312.50 million to $333.20 million. For the next financial year, analysts anticipate that the business will report sales of $395.72 million, with estimates ranging from $329.00 million to $459.09 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.07. Amphastar Pharmaceuticals had a net margin of 0.74% and a return on equity of 5.14%. The company had revenue of $79.79 million during the quarter, compared to analysts’ expectations of $76.21 million. During the same quarter in the prior year, the company earned $0.05 EPS. Amphastar Pharmaceuticals’s revenue was up 36.7% compared to the same quarter last year.

Several analysts recently issued reports on AMPH shares. Wells Fargo & Co set a $29.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 6th. Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research note on Wednesday, July 10th. Finally, BidaskClub raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $24.64.

In other news, insider Jason B. Shandell sold 6,615 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $20.31, for a total value of $134,350.65. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Rong Zhou sold 9,600 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $22.76, for a total transaction of $218,496.00. Following the completion of the transaction, the executive vice president now owns 66,707 shares in the company, valued at $1,518,251.32. The disclosure for this sale can be found here. Insiders own 30.80% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Hillsdale Investment Management Inc. lifted its position in Amphastar Pharmaceuticals by 25.2% during the second quarter. Hillsdale Investment Management Inc. now owns 33,800 shares of the company’s stock valued at $714,000 after buying an additional 6,800 shares in the last quarter. Swiss National Bank lifted its position in Amphastar Pharmaceuticals by 2.2% during the second quarter. Swiss National Bank now owns 64,400 shares of the company’s stock valued at $1,359,000 after buying an additional 1,400 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its position in Amphastar Pharmaceuticals by 225.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 60,800 shares of the company’s stock valued at $1,268,000 after buying an additional 42,100 shares in the last quarter. First Trust Advisors LP acquired a new position in Amphastar Pharmaceuticals during the second quarter valued at approximately $2,440,000. Finally, Rothschild & Co. Asset Management US Inc. lifted its position in Amphastar Pharmaceuticals by 10.8% during the second quarter. Rothschild & Co. Asset Management US Inc. now owns 347,523 shares of the company’s stock valued at $7,336,000 after buying an additional 33,957 shares in the last quarter. Hedge funds and other institutional investors own 47.46% of the company’s stock.

NASDAQ AMPH traded down $0.20 during trading hours on Friday, hitting $19.87. 139,348 shares of the company’s stock traded hands, compared to its average volume of 143,241. Amphastar Pharmaceuticals has a 52-week low of $16.18 and a 52-week high of $25.43. The company has a market cap of $944.60 million, a P/E ratio of 94.62 and a beta of 1.35. The company has a quick ratio of 1.35, a current ratio of 2.06 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average is $20.27.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Article: Initial Public Offering (IPO)

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.